|
Scott Silverman joined Atlas Venture in 2004 and is a Principal in the life sciences sector with responsibilities across both the private and public portfolio.
Previously, Scott worked at the life science venture capital firm Oxford Bioscience Partners and as a strategy and management consultant at The Boston Consulting Group (BCG). At BCG, he specialized in the technology and healthcare practice areas and served in the New York, Boston and Paris offices.
Scott has been involved with a number of Atlas Venture portfolio companies, including: Adnexus Therapeutics, Alnylam (Nasdaq: ALNY), Aureon Laboratories, Helicos Biosciences, InfaCare Pharmaceuticals, IVREA Pharmaceuticals (Board Member), Momenta (Nasdaq: MNTA), Resolvyx Pharmaceuticals, Stromedix and Vitae Pharmaceuticals. Scott has played a significant role in the formation and first institutional financing of eight companies. He serves on the Board of Ivrea Pharmaceuticals and Stromedix.
As a Keasbey Memorial Scholar, Scott received his Doctorate in Clinical Molecular Genetics from Oxford University’s Weatherall Institute of Molecular Medicine. Scott also graduated Phi Beta Kappa and with High Honors from Dartmouth College with a Bachelor of Arts in Biochemistry and Molecular Biology. His research has included investigating the post-translational modification of proteins associated with various human diseases, such as cancer and cystic fibrosis, as well as an original discovery related to RNAi. Scott’s work has been published and reviewed in several scientific journals.
Investment Sector : Life Sciences
Portfolio Companies :
Adnexus Therapeutics, Aureon Laboratories, Helicos BioSciences, InfaCare Pharmaceuticals, Momenta, Resolvyx Pharmaceuticals, Vitae Pharmaceuticals
Boards :
IVREA Pharmaceuticals, Stromedix
In the News:
Helicos BioSciences to Ring NASDAQ Closing Bell on July 2, 2007
Helicos BioSciences Announces Commencement of Commercial Manufacturing
Presentation at Piper Jaffray’s 2nd Annual London Health Care Conference - 21 June 2007
Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch
Momenta Pharmaceuticals to Present At the Sixth Annual Needham Biotechnology & Medical Technology Conference
Dr. Patrice Milos Joins Helicos BioSciences as Chief Scientific Officer
Helicos Biosciences Prices Initial Public Offering
Momenta Pharmaceuticals to Present At the Bank of America Health Care Conference
Momenta Pharmaceuticals to Present At the Citigroup 2007 Healthcare Conference
Momenta Pharmaceuticals Announces Date for 2007 Annual Meeting of Stockholders
Momenta Pharmaceuticals to Present At the Acumen BioFion Rodman & Renshaw 4th Annual Global Healthcare Conference
Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation
Helicos Sets IPO at 5.4 mln Shares, $13-$15 | 